-
Something wrong with this record ?
Outline of therapeutic interventions with muscarinic receptor-mediated transmission
J. Jakubík, E. Šantrůčková, A. Randáková, H. Janíčková, P. Zimčík, V. Rudajev, P. Michal, E. E. El-Fakahany, V. Doležal
Language English Country Czech Republic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Muscarinic Agonists therapeutic use MeSH
- Muscarinic Antagonists therapeutic use MeSH
- Humans MeSH
- Nervous System Diseases drug therapy metabolism MeSH
- Neurons drug effects metabolism MeSH
- Receptors, Muscarinic drug effects metabolism MeSH
- Signal Transduction drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Muscarinc receptor-mediated signaling takes part in many physiological functions ranging from complex higher nervous activity to vegetative responses. Specificity of action of the natural muscarinic agonist acetylcholine is effected by action on five muscarinic receptor subtypes with particular tissue and cellular localization, and coupling preference with different G-proteins and their signaling pathways. In addition to physiological roles it is also implicated in pathologic events like promotion of carcinoma cells growth, early pathogenesis of neurodegenerative diseases in the central nervous system like Alzheimer's disease and Parkinson's disease, schizophrenia, intoxications resulting in drug addiction, or overactive bladder in the periphery. All of these disturbances demonstrate involvement of specific muscarinic receptor subtypes and point to the importance to develop selective pharmacotherapeutic interventions. Because of the high homology of the orthosteric binding site of muscarinic receptor subtypes there is virtually no subtype selective agonist that binds to this site. Activation of specific receptor subtypes may be achieved by developing allosteric modulators of acetylcholine binding, since ectopic binding domains on the receptor are less conserved compared to the orthosteric site. Potentiation of the effects of acetylcholine by allosteric modulators would be beneficial in cases where acetylcholine release is reduced due to pathological conditions. When presynaptic function is severely compromised, the utilization of ectopic agonists can be a thinkable solution.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008945
- 003
- CZ-PrNML
- 005
- 20170221092349.0
- 007
- ta
- 008
- 150305s2014 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.932675 $2 doi
- 035 __
- $a (PubMed)24564657
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Jakubík, Jan $7 xx0281420 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 245 10
- $a Outline of therapeutic interventions with muscarinic receptor-mediated transmission / $c J. Jakubík, E. Šantrůčková, A. Randáková, H. Janíčková, P. Zimčík, V. Rudajev, P. Michal, E. E. El-Fakahany, V. Doležal
- 520 9_
- $a Muscarinc receptor-mediated signaling takes part in many physiological functions ranging from complex higher nervous activity to vegetative responses. Specificity of action of the natural muscarinic agonist acetylcholine is effected by action on five muscarinic receptor subtypes with particular tissue and cellular localization, and coupling preference with different G-proteins and their signaling pathways. In addition to physiological roles it is also implicated in pathologic events like promotion of carcinoma cells growth, early pathogenesis of neurodegenerative diseases in the central nervous system like Alzheimer's disease and Parkinson's disease, schizophrenia, intoxications resulting in drug addiction, or overactive bladder in the periphery. All of these disturbances demonstrate involvement of specific muscarinic receptor subtypes and point to the importance to develop selective pharmacotherapeutic interventions. Because of the high homology of the orthosteric binding site of muscarinic receptor subtypes there is virtually no subtype selective agonist that binds to this site. Activation of specific receptor subtypes may be achieved by developing allosteric modulators of acetylcholine binding, since ectopic binding domains on the receptor are less conserved compared to the orthosteric site. Potentiation of the effects of acetylcholine by allosteric modulators would be beneficial in cases where acetylcholine release is reduced due to pathological conditions. When presynaptic function is severely compromised, the utilization of ectopic agonists can be a thinkable solution.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a agonisté muskarinových receptorů $x terapeutické užití $7 D018721
- 650 _2
- $a antagonisté muskarinových receptorů $x terapeutické užití $7 D018727
- 650 _2
- $a nemoci nervového systému $x farmakoterapie $x metabolismus $7 D009422
- 650 _2
- $a neurony $x účinky léků $x metabolismus $7 D009474
- 650 _2
- $a receptory muskarinové $x účinky léků $x metabolismus $7 D011976
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dolejší, Eva $7 xx0211134 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Randáková, Alena $7 _AN067460 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Janíčková, Helena $7 xx0283376 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Zimčík, Pavel $7 _AN081836 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Rudajev, Vladimír $7 jo20211124170 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Michal, Pavel $7 _BN002852 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a El-Fakahany, E. E. $u Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, United States of America
- 700 1_
- $a Doležal, Vladimír $7 _BN002742 $u Department of Neurochemistry, Institute of Physiology Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 63, Suppl. 1 (2014), s. S177-S189
- 773 0_
- $t 60 years Institute of Physiology, Academy of Sciences of the Czech Republic $g (2014), s. S177-S189 $w MED00190345
- 856 41
- $u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20150305 $b ABA008
- 991 __
- $a 20170221092541 $b ABA008
- 999 __
- $a ok $b bmc $g 1066862 $s 891748
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 63 $c Suppl. 1 $d S177-S189 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2014 $d S177-S189 $m 60 years Institute of Physiology, Academy of Sciences of the Czech Republic $x MED00190345
- LZP __
- $b NLK118 $a Pubmed-20150305